GSK plc has identified cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors and their prodrugs reported to be useful for the treatment of systemic lupus erythematosus or lupus nephritis.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Hepaitech (Beijing) Biopharma Technology Co. Ltd. has patented compounds reported to be useful for the treatment of anemia, fungal infections and HIV infections, among others.
Beijing Tide Pharmaceutical Co. Ltd. has described orydalmine derivatives reported to be useful for the treatment of pain, depression, and substance abuse and dependence.
Impact Therapeutics (Shanghai) Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have presented compounds reported to be useful for the treatment of gram-negative bacterial infections.